Table 1 Detailed demographic, clinical, laboratory features and drug history of 53 SLE patients
Parameters | Values |
|---|---|
Sex (M/F) | 7/46 |
Age (years; mean ± SD) | 32.5 ± 10.6 |
Disease duration (months; mean ± SD) | 65 ± 30.6 |
SLEDAI (mean ± SD) | 8.8 ± 3.7 |
Lupus nephritis (n/%) | 19/35.85 |
Arthritis (n/%) | 14/26.4 |
Malar rash (n/%) | 8/15.1 |
Alopecia (n/%) | 5/9.4 |
Neurologic manifestations (n/%) | 21/39.6 |
Serositis (n/%) | 2/3.77 |
RP+ (n/%) | 8/15.1 |
Anemia (hemoglobin < 12 g/dl) (n/%) | 37/69.8 |
Leukopenia (n/%) | 8/15.1 |
Thrombocytopenia (n/%) | 9/17 |
ANA (n/%) | 53/100 |
Anti-dsDNA (n/%) | 51/98 |
APL+ (n/%) | 15/28.3 |
ACL+ (n/%) | 10/18.9 |
Low complement level (C3 < 80 mg/dl, C4 < 12 mg/dl) (n/%) | 20/37.3 |
ESR (> 20 mm/h) (n/%) | 35/66.04 |
Treatment | |
Azathioprine (n/%) | 34/64.15 |
Hydroxychloroquine (n/%) | 21/39.6 |
Prednisone (n/%) | 51/96.2 |